Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049665 | 0.83 | PIK3CA (0.36) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL391776 | 0.78 | PDE4A (0.44) | PIK3CAPIK3R1HIF1AABCB1FABP4 | |
| Hydrochloric Acid SCHEMBL4518915 | 0.77 | PDE4A (0.43) | PIK3CAPIK3R1HIF1AABCB1FABP4 | |
| SCHEMBL390178 | 0.72 | MPL (0.40) | PIK3CAMTORPIK3CBPIK3CGPRKCI | |
| Hydrochloric Acid SCHEMBL4518145 | 0.72 | MPL (0.39) | PIK3CAMTORPIK3CBPIK3CGPRKCI | |
| Hydrochloric Acid SCHEMBL4508187 | 0.71 | PIK3CA (0.41) | PIK3CAPIK3R1MAPTMTORPIK3CB | |
| SCHEMBL4518887 | 0.70 | PIK3CA (0.39) | PIK3CAPIK3R1HIF1AABCB1MAPT | |
| SCHEMBL386949 | 0.70 | NPC1 (0.42) | PIK3CAPIK3R1MAPTMTORPIK3CB | |
| Hydrochloric Acid SCHEMBL4524068 | 0.69 | NPC1 (0.41) | PIK3CAPIK3R1MAPTMTORPIK3CB | |
| SCHEMBL388188 | 0.69 | PRKCI (0.40) | PIK3CAPIK3R1HIF1AABCB1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-7557112-B2 | Aromatic-ring-fused pyrimidine derivative | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | PIK3CA 1482/4885PIK3R1 1626/4885SIRT2 2304/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | PIK3CA 1482/4885PIK3R1 1626/4885SIRT2 2304/4885 |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | PIK3CA 158/4885PIK3R1 413/4885SIRT2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.